ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that the database for Phase 2 clinical trial with RGN-259 for the treatment of dry eye syndrome has been locked and preliminary data analysis should be available the week of October 31st. The analysis will include primary and secondary endpoints, as well as other key parameters identified in the clinical protocol. The double-masked, placebo-controlled clinical trial is assessing the safety and efficacy of RGN-259, the Company’s proprietary preservative-free eye drops, in reducing signs and symptoms of dry eye. Patients received RGN-259 or placebo twice daily for 30 days. Signs and symptoms of dry eye, such as the degree of ocular surface damage and ocular discomfort, were graded periodically during and following the treatment period. The trial is being conducted by Ora Inc., an ophthalmic contract research organization that specializes in dry eye research and clinical trials.
